Could older kidney patients take fewer drugs? new trial aims to find out

NCT ID NCT06568549

Recruiting now Disease control Sponsor: Mayo Clinic Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looks at whether older kidney transplant patients (55 and up) can safely stop taking one of their standard immunosuppressant drugs, mycophenolate mofetil (MMF). About 350 participants will be randomly assigned to either continue MMF or stop it, while staying on other medications. The goal is to see if reducing drugs lowers side effects without increasing the risk of kidney rejection or failure.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Mycophenolate Mofetil (MMF, also known as CellCept)
What this could lead to: If successful, this could show that older kidney transplant patients can safely take fewer immunosuppressant drugs, reducing side effects like infections and other complications.
What could go wrong: This is a Phase 4 trial, so the drugs are already approved, but withdrawing MMF may increase the risk of kidney rejection or graft failure. Results may not apply to younger patients or those with other transplants.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for KIDNEY TRANSPLANTATION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

KIDNEY TRANSPLANTATION MYCOPHENOLATE MOFETIL

Contacts and locations

Locations

Mayo Clinic
RECRUITING

Phoenix, Arizona, 85054, United States
Mayo Clinic
RECRUITING

Jacksonville, Florida, 32224, United States
Mayo Clinic
RECRUITING

Rochester, Minnesota, 55905, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.